IRADIMED came into this earnings season priced for excellence, trading on a rich P/E and riding years of steady profit expansion. Then Q3 2026 hit and the stock dropped about 11% in a single session. That sharp move jars with what the report actually showed. Revenue reached a record US$24.2 million and basic earnings per share landed at roughly US$0.51. The real story is not a collapse in performance; it is a strong top line and solid profitability colliding with investor expectations that were already set very high.
Love IRADIMED's record Q3 revenue but concerned that a rich P/E leaves little room for earnings missteps? Consider using our screener of resilient quality stocks with more balanced expectations through the 29 resilient stocks with low risk scores .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):US$24.2 million vs. US$21.2 million (up about 14%)
-
Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025):US$6.5 million vs. US$5.6 million (up about 17%)
-
Basic EPS (Q3 2026 vs Q3 2025):US$0.51 vs. US$0.44 (up about 16%)
-
Net Profit Margin (Trailing 12 Months vs Prior Year):26.8% vs. 26.3% (margins slightly higher year over year)
Tired of wading through dense earnings releases and spreadsheets for IRADIMED? See the whole story in charts, with a clear view of its valuation picture, through our company report for IRADIMED.
IRADIMED bullish narrative meets real execution markers
Treatment of IRADIMED as a replacement cycle machine depends on more than hype. It rests on whether new hardware and recurring add ons are actually scaling.
"The introduction and FDA approval of the new 3870 MRI compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers."
Record Q3 revenue, record 3870 pump and 3880 monitor bookings, plus over 400 3870 systems produced, show that this refresh is happening in the field. Mix helps too. Quad channel systems and higher average selling prices, along with 21% disposables growth and faster maintenance and service revenue, point to early progress on the longer haul recurring goals.
IRADIMED bear case on margin strain and expectations
The worry is not whether IRADIMED can sell pumps. It is whether that volume arrives without eroding profitability or exposing how tightly expectations are set.
"The initial 3870 production ramp has already led to a lower gross margin compared with a year earlier because of higher manufacturing costs and inefficiencies, and if the effort to restore past manufacturing efficiency takes longer than management expects, Iradimed could face sustained pressure on gross margin and net income even if top line growth remains intact."
Gross margin improved by about 2 percentage points sequentially to roughly 76% as 3870 volumes scaled, and management flags a path back toward historical 77% to 78%. That is a partial rebuttal. Yet the tightened full year EPS range, with the top end trimmed, and a share price that fell about 11% after Q3, show how sensitive the stock remains to any hint that production discipline may cap near term upside.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all .
Hunt Mispriced Stories Before They Move
IRADIMED just showed how a strong operational update can collide with fragile sentiment. The real opportunity could sit in stocks where fundamentals improve before valuations fully adjust.
-
Company 1 - 38% below our estimate - uses new capacity expansion and HELM engines to pursue rising power demand from large data center contracts.
-
Company 2 - 47% below our estimate - turns heavy AI infrastructure and data center spending into advertising tools and messaging products that help businesses target customers.
-
Company 3 - 32% below our estimate - wins large AI workloads by supplying superclusters that extend a partner's cloud platform for training and serving generative models.
Three companies from the same screener. Open every one of the 33 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IRMD .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
